Immatics (IMTX) Total Liabilities (2019 - 2026)
Immatics (IMTX) posted Total Liabilities of $654.6 million for Q4 2025, up 7.98% sequentially from $606.2 million in Q3 2025, and down 12.01% YoY from $743.9 million in Q4 2024.
Analysis
Immatics (IMTX) Total Liabilities (2019 - 2026) Analysis & Trends
Immatics has reported Total Liabilities for 7 years, with the latest figure at $654.6 million in Q4 2025.
- Quarterly Total Liabilities fell 12.01% year-over-year to $654.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $654.6 million (down 12.01% YoY) and the FY2025 annual result came in at $635.3 million, down 15.68% from the prior year.
- Total Liabilities rose to $654.6 million in Q4 2025 per IMTX's latest filing, from $606.2 million in the prior quarter.
- Over five years, Total Liabilities peaked at $743.9 million in Q4 2024 and troughed at $193.7 million in Q2 2021.
- A 5-year average of $391.4 million and a median of $337.0 million in 2022 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2024 and 2025: Total Liabilities slumped 54.32% in 2024, then jumped 178.7% in 2025.
- Over 5 years, Total Liabilities stood at $199.8 million in 2021, then rose by 4.41% to $208.6 million in 2022, then jumped by 50.78% to $314.5 million in 2023, then surged by 136.5% to $743.9 million in 2024, then decreased by 12.01% to $654.6 million in 2025.
- According to Business Quant data, Total Liabilities over the past three periods registered $654.6 million, $606.2 million, and $642.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 4.20 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.72 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 4.00 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 10.03 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - | 555.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 555.40 Mn |
| Mar 31, 2026 | 102.40 Mn |
| Dec 31, 2025 | 711.87 Mn |
| Sep 30, 2025 | 119.10 Mn |
| Jun 30, 2025 | 692.25 Mn |
| Mar 31, 2025 | 110.54 Mn |
| Dec 31, 2024 | 129.62 Mn |
| Sep 30, 2024 | 217.52 Mn |
| Jun 30, 2024 | 264.59 Mn |
| Mar 31, 2024 | 281.36 Mn |
| Dec 31, 2023 | 314.55 Mn |
| Sep 30, 2023 | 206.50 Mn |
| Jun 30, 2023 | 398.24 Mn |
| Mar 31, 2023 | 191.49 Mn |
| Dec 31, 2022 | 208.61 Mn |
| Sep 30, 2022 | 243.25 Mn |
| Jun 30, 2022 | 259.68 Mn |
| Mar 31, 2022 | 186.53 Mn |
| Dec 31, 2021 | 172.26 Mn |
| Sep 30, 2021 | 193.11 Mn |